Generate Biomedicines
GENB
Generate Biomedicines (GENB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $30.00 | Oct 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 | Sep 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $25.00 | Aug 28, 2026 |
| Morgan Stanley | Maintained | Overweight | $22.00 from $20.00 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $16.00 | May 8, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $16.00 | Apr 13, 2026 |
| Goldman Sachs | Initiated Coverage | Buy | $26.00 | Mar 24, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $24.00 | Mar 24, 2026 |
| Guggenheim | Initiated Coverage | Buy | $30.00 | Mar 24, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $20.00 | Mar 24, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 24, 2026 |
Frequently asked questions
What is the latest analyst rating on GENB?
On Oct 5, 2026, HC Wainwright & Co. maintained Generate Biomedicines at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.